Loading…
Loading…
CTABF (Canntab Therapeutics Limited) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CTABF and 80,000+ other tickers.
See exactly how CTABF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CTABF and 80,000+ other tickers.
Canntab Therapeutics Limited is a Canadian phytopharmaceutical firm dedicated to pioneering the research and development of sophisticated, pharmaceutical-grade cannabinoid preparations. The company manufactures various oral cannabis medications, including extended-release cannabinoid pills and pellets, rapidly acting cannabidiol formulations, multi-layered modified-release options, quick-dissolving flash-melt products, and dual-layer cannabinoid tablets. These offerings target a broad spectrum of health issues, such as sleep disturbances, post-traumatic stress disorder, social anxiety…
Toronto, Ontario--(Newsfile Corp. - le 14 juin/June 2024) - The common shares of Canntab Therapeutics Limited will be delisted from the CSE at market close today, June 14, 2024. Canntab Therapeutics is currently suspended.
Toronto, Ontario--(Newsfile Corp. - September 18, 2023) - Canntab Therapeutics Limited (CSE: PILL) (OTC Pink: CTABF) (FSE: TBF1) (the "Corporation") announces that the Ontario Securities Commission (the "OSC") has rejected the Corporation's application for a management cease trade order (the "MCTO") dated September 14, 2023, as the Corporation is not viewed as having met all of the criteria for an MCTO. The Corporation filed the MCTO application with the OSC due to an anticipated delay in filing its audited annual financial statements and management discussion & analysis for the financial year ended May 31, 2023, and the certification of the foregoing filings as required by National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings (collectively, the "Documents").
Canntab Therapeutics Ltd (CSE:PILL, OTCQB:CTABF) has provided an update on several matters impacting the company, including plans to move its manufacturing operations following expiry of its lease at the Markham facility. The company, which is a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, said it has undertaken a strategic review in recent months of its domestic operations in the context of the global market.
Canntab Therapeutics Limited has provided an update on the recent product delivery of its unique pharmaceutical cannabinoid solutions to the Nova Scotia Liquor Corporation (NSLC). The company said that on August 15, 2022, it completed its first shipment of 5mg and 10mg THC InstaCann tablets to the NSLC, totaling 300 bottles of each SKU.
Canntab Therapeutics Ltd said it has appointed Hamish Sutherland as a strategic business consultant to develop additional sales and distribution channels for the company's products and to assist it in reaching strategic partnerships in the cannabis industry. A seasoned veteran of the legal cannabis industry in Canada with over nine years of experience, Sutherland's past achievements include the role of founding chief operating officer of Bedrocan Canada Inc., delivering over $750 million in investor value and overseeing the building and commissioning of two licensed facilities, including a 52,000 square foot state-of-the-art automated facility in suburban Toronto.